Por Jose Pulido
June 22, 2023
Can you help me paraphrase this note: Clivi, the Mexican startup specializing in diabetes care, raised US$10 million in its seed round through a co-led investment by Dalus Capital and Foundation Capital, with the participation of a group of investors, including Cathay Innovation through its C. Entrepreneurs fund, FEMSA Ventures, Quiet Capital, 500, Next Billion Ventures, and Conexo.
The healthtech company plans to utilize the capital to finalize the development of its product and its artificial intelligence technology that automates functions, enabling doctors to enhance their capacity to treat patients.
In addition to the initial group of investors, angel investors such as Ricardo Weder, founder and CEO of Jüstor; Adalberto Flores, founder and CEO of Kueski; Suresh Batchu, co-founder of Trust Networks; Ariel Lambrecht, founder and CEO of Mara; Tara Syed, executive at Meta; and the co-founders of Reina Madre, Vicente Aristegui and Juan Moctezuma, have joined in.
You may also be interested in reading: VIOO, the Mexican startup focused on visual content creation, raises a seed round of $1 million
Ricardo Moguel, founder and CEO of Clivi, highlighted the shortage of endocrinologists in Mexico, with an average of one specialist for nearly 10,000 patients. This means that patients can only see a doctor every three months, despite chronic diseases like diabetes requiring daily decision-making. Aware of this need, Clivi has developed a platform that combines the human aspect with technology, connecting patients with endocrinologists, nutritionists, and psychologists.
Furthermore, users can access monitoring and treatment plans through their preferred communication channel, such as WhatsApp, to improve their adherence to treatment goals and lifestyle changes.
Clivi not only provides the necessary medical support but also supplies all the required equipment, such as glucose meters, test strips, blood testing kits, as well as the required medications.
Since its launch in October 2021, Clivi’s platform has assisted thousands of patients and takes pride in achieving a 94% diabetes control rate within six months. Additionally, the company is experiencing steady growth, with an average of 2,000 new patients joining the platform each month.
For detailed information, visit: Foundation Capital
November 20, 2024
October 29, 2024